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Objectives: Over the last decade, the number of endovascular procedures performed on the superficial femoral (SFA) and
popliteal arteries (PA) has significantly increased. There is no consensus on the optimal form of intervention used in this
arterial segment. While some have advocated balloon angioplasty alone, others have championed either selective or
primary stenting of these lesions. It is the purpose of this study to determine the efficacy and durability of primary
stenting of the superficial femoral and popliteal artery.
Methods: All patients undergoing peripheral angioplasty by a single vascular surgeon were prospectively enrolled in an
Institutional Review Board-approved, primary-stenting protocol. During a 44-month period, all patients undergoing
percutaneous transluminal angioplasty of the SFA or PA also received primary arterial stenting with bare, self-expanding
nitinol stents. Patient demographics and risk factors were identified. TransAtlantic InterSociety Consensus (TASC) classifi-
cationswere determined for all lesions. Loss of primary patencywas said to have occurredwhen anocclusionor a 50%or greater
stenosis in any treated arterial segment was diagnosed by arterial duplex or angiography. Only time to loss of primary patency
was recorded. Kaplan-Meier survival curves were plotted and differences between groups tested by log rank method.
Results:Between January 16, 2004 and August 13, 2007, 201 angioplasties with primary stenting were performed on 161
patients. One hundred twenty-three stents were placed for claudication, and 78 for critical limb ischemia. Forty-six
segments treated were TASCA, 82 were TASC B, 38 were TASCC, and 35 were TASCD. Patient follow-up ranged from
three to 1329 days (mean: 426 days). Primary patency rates for TASC A and B lesions were 79%, 67%, and 57% at 12, 24,
and 36 months. For TASC C and D lesions, primary patency rates were 52.7%, 36%, and 19% at the same time intervals.
Primary patency rates for TASC A and B lesions were significantly higher than for C and D lesions (P < .001). The limb
salvage rate was 88.5% in patients with critical limb ischemia. Distal runoff did not influence patency (P  .827).
Conclusions: Primary stenting of the SFA and PA provides durable results in patients with TASC A and B lesions and may
be an effective treatment strategy. This approach is significantly less effective when used in treating those with TASC
C and D disease. Based on the results in this series, the use of primary stenting does not extend the anatomic limits
of the current treatment recommendations for catheter-based intervention in patients with infrainguinal occlusive
disease. ( J Vasc Surg 2009;50:542-8.)It has been over 30 years since Gruntzig introduced the
modern balloon angioplasty catheter and ushered in the
contemporary era of the percutaneous treatment of periph-
eral arterial disease.1 The aging of our population and the
resultant increase in the prevalence of peripheral vascular dis-
ease has led to an explosive rise in the number of catheter-
based procedures being performed in patients with lower limb
ischemia.2 Since endovascular procedures are often used as a
first line treatment for lower extremity ischemia, it is becom-
ing increasingly important to determine whichmodes of ther-
apy are the most durable and cost effective.
While the results of percutaneous treatment of iliac lesions
have approached that of open procedures,3 the same cannot
be said for angioplasty (PTA) of the infrainguinal vessels.
Routine treatment of the superficial femoral artery (SFA)with
balloon expandable stainless-steel stents has been shown to be
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542no more durable than angioplasty alone.4-8 In hopes of im-
proving on the patency of PTA, some have suggested the use
of alternative therapies such as atherectomy, cryoplasty, or the
deployment of polytetraflourethylene covered stent grafts in
the SFA with varying success.9-15
In 1963, while working for U.S. Naval Ordinance, W.J.
Buehler discovered the shapememory properties of the binary
nickel-titanium alloy later called nitinol.16 With its enhanced
flexibility, it has been used extensively as an adjunct to angio-
plasty in hopes of improving the durability of endovascular
procedures performed on the superficial femoral and popliteal
arteries. While some have reserved the use of these stents for
salvage following unsuccessful PTA,17-22 others have pro-
moted primary nitinol stenting as the preferred endovascular
method of treating infrainguinal occlusive disease.23-27 Few
prospective studies have evaluated the efficacy of this treat-
ment strategy. It is the purpose of this study to prospectively
determine the durability of angioplasty combined with pri-
mary nitinol stenting when it is used to treat occlusive disease
of the superficial femoral and popliteal arteries.
METHODS
During a 44-month period, all patients consenting to
an Institutional Review Board-approved primary stenting
protocol for percutaneous treatment of the SFA and pop-
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having orificial occlusion of the SFA and patients with total
occlusion of the SFA, PA, and proximal tibial vessels had no
attempts at percutaneous interventions and were preferen-
tially treated surgically. The remaining patients were in-
cluded in the primary stenting study protocol. Interventions
were performed by or under the supervision of one vascular
surgeon (SGK) Data were collected according to the guide-
lines set forth by the Society for Vascular Surgery28 and
stratified by the second TransAtlantic InterSocietal Consen-
sus (TASC II) classification.29 Patient gender, demograph-
ics, presence of co-morbidities, history of smoking, and the
use of anticoagulation therapy were recorded. Indication
for intervention, location and length of the arterial lesion,
diameter of angioplasty balloon, size and type of stent
deployed, and quality of distal runoff were noted. Poor
distal runoff was defined as the visualization on angiogra-
phy of one or no tibial runoff distal to the site of interven-
tion. Type and number of secondary interventions were
noted. Complications including significant hematomas
(those requiring transfusion, operative intervention, or
prolonged hospitalization), myocardial infarction, distal
embolization, or death were recorded.
Interventions were performed in an angiography suite
with fixed imaging. Procedures were most frequently per-
formed from the contra-lateral groin using six or seven
French sheaths. Lesions were preferentially crossed using
.035-inch hydrophilic guide wires supported by 4F angled
glide catheters. Stenotic lesions were crossed in an intra-
luminal fashion, whilemost occlusions greater than 5 cmwere
traversed in a subintimal plane. In the latter part of the series,
re-entry devices were occasionally used to enter the artery
distal to an occlusive lesion. After angiographic confirmation
of position in the true lumen, stenoses and occlusions were
dilated with five or six-millimeter non-compliant balloons
inflated to six to twelve atmospheres of pressure for a duration
of 30 to 45 seconds. Self-expanding nitinol stents were de-
ployed across all segments undergoing PTA. One centimeter
of overlap was used when multiple stents were required to
cover a treated arterial segment as per manufacturers’ recom-
mendations. Stents were chosen on the basis of supply and
surgeon preference. All patients received 300 mg of clopridi-
grel and325mgof aspirin prior to the procedure. Seventy-five
mg of clopridogrel and 81 mg of aspirin were maintained for
at least 30 days post intervention. Low dose aspirin was
continued indefinitely. All patients received 5000 units of
heparin prior to PTA. Anticoagulation was not reversed at the
conclusion of the procedure. Initial procedural success was
considered to have occurred when less than 30% stenosis
remained in the treated vessel.
All patients received duplex scans within 30 days of
intervention and at six-month intervals thereafter. Loss of
primary patency was considered to have occurred with
vessel occlusion, or when a 50% or greater restenosis at the
previous site of angioplasty and stenting was noted whether
or not intervention was undertaken. A 50% stenosis was said
to be present when a peak systolic velocity of at least 200 cm
per second and a 3:1 velocity ratio was seen across thelesion. Time to loss of primary patency was recorded and
used as our primary and only outcome measure when
plotting survival curves.
Demographic and comorbidity data was recorded per
patient and patency data was calculated on a per limb basis.
Kaplan-Meier survival curves were calculated on intent to
treat basis and differences tested by log rankmethod. Univar-
iate analysis was performed on factors thought to affect the
primary patency of the percutaneous intervention. Compari-
sons were made between those patients who lost primary
patency and those who did not using Cox proportional haz-
ards model. Factors found to be significant in the univariate
analysis were then included in a step-wise multivariate Cox
proportional hazards regression model to determine individ-
ual significance in the presence of other factors. Statistical
significance was assumed at a P value of less than .05.
RESULTS
Between January 2004 and August 2007, 219 diagnos-
tic lower extremity angiograms were performed. Twenty-
three patients had orificial occlusion of the SFA, 29 patients
had occlusion of the SFA, PA, and proximal tibial vessels,
and six patients declined endovascular intervention. These
patients were excluded from the study. Two hundred and
one procedures were performed on 161 patients. Seventy-
one patients were male, and 90 were female. Their ages
ranged from 42 to 91 years (mean: 76.2  11 years). One
hundred seventeen patients had hypertension (72.6%), 84
(55.3%) had significant coronary artery disease, 80 (52.6%)
had a history of hypercholesterolemia, 66 (43.4%) had
clinically evident diabetes, 43 (28.3%) were active smokers,
29 (18%) patients had a creatinine 2.0 of which 11 (7.2%)
were dialysis dependent, and six (3.9%) were on chronic
warfarin anticoagulation.
One hundred twenty-three (61.2%) procedures were
performed for claudication, 34 for rest pain (16.9%), and
44 (21.9%) for open ulceration or gangrene. Forty-four
percent of the treated lesions were in the SFA, 17% were in
the popliteal artery, and 39% spanned both arterial seg-
ments. The above-knee popliteal segment was treated in 85
limbs and the below-knee segment in 19 limbs. Forty-six
limbs were classified as TASC A (22.9%), 82 TASC B
(40.8%), 38 TASC C (18.9%), and 35 TASC D (17.4%).
Themean length of arterial segment treated was 12.9 9.4
centimeters (range: 1-45 cm). Forty-three percent of limbs
treated had areas of occlusion and 57% had only stenotic
lesions. The average number of stents placed in TASC A
and B lesions was 1.2 (range: 1-2) and 2.5 in TASC C and
D lesions (range: 1-6). Stent brands and their frequency of
use are listed in Table I. Runoff was classified as good in 91
limbs (47.4%) and poor in 110 (52.6%).
Initial success of angioplasty and stenting was 95.6%.
Mean duration of follow-up was 426 days (range: 3-1329
days), and the median duration was 348 days. Overall
primary patency at three years was 38.7% (Fig 1). Primary
patency rates at 12, 24, and 36 months were 79%, 67%, and
57% for TASCA and B lesions and 52.7%, 36%, and 19% for
TASC C and D lesions (Fig 2). The standard error for
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10% at 40 months of follow-up. This difference as tested by
log rank method was highly significant (P  .001). In
univariate analysis, history of hypercholesterolemia, limb
threat, and TASC C or D stratification negatively impacted
the primary patency of the interventions (Table II). In multi-
variate analysis, only history of hypercholesterolemia and
TASC classification were found to be statistically significant
(Table III). Balloon diameter, stent diameter, and brand of
stent did not significantly influence primary patency (P 
.25). Stent fractures were noted in two treated segments, and
both were associated with loss of primary patency.
Twenty-five secondary endovascular interventions were
performed on 24 extremities. Twenty-two re-interventions
were performed for intra-stent stenosis; 19 remain patent after
one intervention while one limb required two procedures to
maintain primary assisted patency. Three interventions were
performed for stent occlusions, of which two remain patent
after a single re-intervention. Runoff scores were reduced in
only three of the above patients following their initial loss of
anatomic patency and only one patient presented with acute
ischemia requiring urgent re-intervention. Eight patients ul-
timately required bypass operations. Limb salvage in pa-
tients with critical limb ischemia was 88.5% and included
four patients who required bypass operations. Five patients
(2.4%) developed significant hematomas following their
procedure (none requiring operative intervention), two
patients (1%) suffered a clinical myocardial infarction, and
one patient (0.5%) had a distal embolus requiring thrombol-
ysis. One patient died within 30 days of the procedure. This
patient with multiple medical comorbidities expired at home
on the 23rd post-procedure day from a presumed myocar-
dial infarction.
DISCUSSION
In many centers, including our own, catheter-based
interventions serve as a first line intervention for many
patients with infrainguinal occlusive disease. Angioplasty
with or without stenting offers the advantage of low mor-
bidity, decreased convalescence, and high patient accep-
tance. However, longevity and cost effectiveness remain a
concern.
In 2007, TASC II made the following recommenda-
tions for treatment of femoropopliteal disease.29 TASC A
lesions are best treated by endovascular therapy and TASC
Table I. Stent brands and frequency of use
Stent type Number (%)
Abbott – Exceed 117 (35%)
Cordis – Smart 87 (26%)
Edwards – Lifestent 67 (20%)
Abbott – Absolute 20 (6%)
Bard – Luminex 21 (6%)
EV3 – Protégé 13 (4%)
Abbott – Expert 10 (3%)D by surgery. It was also their recommendation that endo-vascular therapy is the preferred treatment for TASC B
lesions while surgery is preferable for TASC C lesions. In
addition, when treating B and C lesions, patient co-
morbidities, patient preference, and operator experience
play an increasingly important role in the decision-making
process.
Technological advances continue to occur at an ever-
increasing pace with the intent of increasing the durability
of infrainguinal endovascular procedures. Some have sug-
gested that primary nitinol stenting of the superficial and
popliteal arteries can provide results that are superior to
angioplasty and selective stenting alone and extend the
anatomic indications for endovascular intervention. How-
ever, these devices add considerable cost to any percutane-
ous intervention and should demonstrate clear benefit be-
fore their routine use can be advocated or current treatment
recommendations changed.
This study was undertaken to determine whether the
addition of primary stenting to angioplasty of the SFA and
popliteal artery would improve the durability of these in-
terventions. Although the design of the current prospective
but non-randomized study precluded the formation of a
concurrent control group, comparisons of our data to
reports in the literature can be made. Primary patency, as
defined by Ahn et al,28 was chosen as our primary outcome
measure as it is the variable least likely to be operator-
dependent. While primary assisted and secondary patency
can be influenced by indications for re-intervention and the
willingness of the interventionalist to repetitively intervene
before resorting to alternative treatment modalities, pri-
mary patency is an objective, direct indicator of the dura-
bility of the primary procedure. While some have been less
stringent in defining primary patency, we believe that ad-
hering to our strict definition allows for more consistent
and unbiased data analysis.
Unlike the present study, very few previous studies on
infrainguinal endovascular therapy have been prospective.
In addition most patients are not stratified according to
TASC classifications, and the results are rarely reported on
intent to treat basis. This lack of consistent reporting stan-
dards for procedural success or failure contributes signifi-
cantly to the difficulty in the interpretation of the available
information. Our study was performed in an attempt to
address some of the gaps in the literature concerning the
value of primary stenting.
Consequently, it is not surprising that the literature
presents conflicting data. Previous studies have shown that
angioplasty alone or with selective stenting have yielded
acceptable rates of primary patency in the treatment of
short segment TASCA and B lesions, but have proven to be
far less effective when used to treat TASC C and D le-
sions.17,20,22,30-32 Our study using primary stenting mir-
rors these results. Recent prospective and randomized stud-
ies involving the treatment of short segment disease of the
SFA have been performed. Two of the three showed benefit
from primary stenting,23,24,33 and the third used a type of
stent that is now rarely used to treat infrainguinal disease.34The 79% one-year primary patency achieved in the TASC A
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Volume 50, Number 3 Dearing et al 545Fig 1. Survival curve showing primary patency for all stented arterial segments. Standard error did not exceed 10%
until 40 months of follow-up. Hatch marks represent events in which a stented segment lost primary patency.Fig 2. Survival curve showing primary patency for TASC A and B versus TASC C and D treated arterial segments.
Standard error did not exceed 10% until 40 months of follow-up. Hatch marks represent events in which a stented
segment lost primary patency. Log rank test: P  .001. TASC A/B, top line. TASC C/D, bottom line.
JOURNAL OF VASCULAR SURGERY
September 2009546 Dearing et aland B group in our study is remarkably similar to the
preliminary results seen in the recently released prospective
and randomized Resilient trial, which was limited to pa-
tients with short segment SFA lesions. This study, pre-
sented at the Cardiovascular Research Foundation’s 19th
Annual Transcatheter Cardiovascular Therapeutics scien-
tific symposium in Washington, D.C. on October 23,
2007, has not yet been published.33
In our study and others, TASC classification signifi-
cantly influenced the results of percutaneous intervention
on the SFA and popliteal arteries.17,20,22,31 It is interesting
to note that the only other variable negatively impacting
patency in this series was a history of hypercholesterolemia.
This contrasts with previous studies including our own that
have shown that other factors, in particular poor run-
off,20,35-37 significantly decrease the primary patency of
Table II. Univariate analysis
Univariate Cox proportional hazards model
Variable Hazards ratio (95% CI) P value
Age 1.01 (0.99-1.04) .365
Gender 1.34 (0.82-2.19) .243
Coronary artery disease 0.93 (0.56-1.54) .778
Diabetes mellitus 1.01 (0.60-1.69) .978
Hypertension 0.83 (0.33-2.08) .695
Hypercholesterolemia 1.73 (1.03-2.90) .039
Chronic obstructive
pulmonary disease 0.823 (0.44-1.55) .546
Chronic renal insufficiency 0.614 (0.18-1.74) .275
Active tobacco smoker 0.873 (0.50-1.53) .636
Coumadin 0.814 (0.11-5.90) .839
Indication
Claudication ref
Rest pain 2.70 (1.44-5.05) .002
Ulcer 1.96 (0.95-3.27) .071
Runoff score 1.03 (0.77-1.39) .827
TASC
A ref
B 2.42 (0.98-5.98) .055
C 3.89 (1.54-9.82) .004
D 7.68 (3.11-18.94) .001
CI, Confidence interval; TASC, TransAtlantic InterSociety Consensus.
Table III. Multivariate analysis
Multivariate Cox proportional hazards model
Variable Hazards ratio (95% CI) P value
Age 1.01 (0.98-1.04) .550
Gender 1.61 (0.92-2.85) .099
Active tobacco smoker 0.88 (0.48-1.60) .670
Hypercholesterolemia 2.06 (1.19-3.57) .010
TASC
A ref
B 2.18 (0.88-5.45) .094
C 3.77 (1.46-9.76) .006
D 6.17 (2.39-15.97) .001
CI, Confidence interval; TASC, TransAtlantic InterSociety Consensus.infrainguinal vessels treated with the technique of angio-plasty and selective stenting. It is unclear why these
factors did not influence the results in our current study,
but one can speculate that the strategy of primary nitinol
stenting in some way alters the risk for anatomic failure in
treated segments of the SFA and popliteal arteries.
Clearly, more data will need to be obtained before any
treatment recommendations based on these observations
can be made
Angioplasty in conjunction with the use of nitinol
stents can be performed on themajority of patients present-
ing with infrainguinal occlusive disease. We found it to be
quite durable in patients with TASC A and B lesions and
less so when more extensive disease is treated. Yet, failure
can often be salvaged by repeat percutaneous intervention,
infrequently precipitates acute ischemia, and rarely pre-
cludes open surgical bypass.
It is of interest that only eight patients in our series
required open bypass surgery. The reasons are multifac-
torial. Many primary treatment failures were salvaged by
repetitive endovascular procedures. A number of pa-
tients with open ulcerations or limited gangrene were
able to heal their lesions before the failure of their
percutaneous interventions. Finally, a group of patients
who lost primary anatomic patency of their stented arte-
rial segments maintained enough hemodynamic benefit
to remain relatively asymptomatic and not require open
operation.
In general, given the results of our study, we now
adhere to the recommendations for percutaneous interven-
tion set forth in TASC II. We aggressively pursue catheter-
based intervention using a policy of selective but liberal
stenting in patients with TASC A and B lesions and in many
patients with TASC C disease. Percutaneous treatment of
TASC D lesions is now reserved for patients with multiple
medical comorbidities or those with inadequate conduit for
surgical bypass. We would also be more likely to employ
angioplasty and selective stenting in patients with TASC D
disease whose indication for intervention is healing of an
ulcer or digital amputation since they may not require as
durable a reconstruction as patients with claudication or
ischemic rest pain.
We conclude that primary stenting of the SFA and
popliteal arteries provides durable results in patients with
TASC A and B lesions and may be an effective treatment
strategy. This approach is significantly less effective when
used in treating those with TASC C and D disease. Based
on the results in this series, the use of primary stenting does
not extend the anatomic limits of the current treatment
recommendations for catheter-based intervention in pa-
tients with infrainguinal occlusive disease.
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